25 XP   0   0   10

Neopharm Co Ltd
Buy, Hold or Sell?

Let's analyse Neopharm Co Ltd together

PenkeI guess you are interested in Neopharm Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Neopharm Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Neopharm Co Ltd

I send you an email if I find something interesting about Neopharm Co Ltd.

Quick analysis of Neopharm Co Ltd (30 sec.)










What can you expect buying and holding a share of Neopharm Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩20,462.03
Expected worth in 1 year
₩22,740.00
How sure are you?
88.2%

+ What do you gain per year?

Total Gains per Share
₩2,277.97
Return On Investment
8.8%

For what price can you sell your share?

Current Price per Share
₩26,000.00
Expected price per share
₩22,350 - ₩29,450
How sure are you?
50%

1. Valuation of Neopharm Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩26,000.00

Intrinsic Value Per Share

₩-103,976.22 - ₩-126,051.39

Total Value Per Share

₩-83,514.19 - ₩-105,589.36

2. Growth of Neopharm Co Ltd (5 min.)




Is Neopharm Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$112m$95.3m$10.7m10.2%

How much money is Neopharm Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$4m$2.9m$1m26.6%
Net Profit Margin24.0%20.1%--

How much money comes from the company's main activities?

3. Financial Health of Neopharm Co Ltd (5 min.)




4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  


Richest
#210 / 394

Most Revenue
#297 / 394

Most Profit
#201 / 394

What can you expect buying and holding a share of Neopharm Co Ltd? (5 min.)

Welcome investor! Neopharm Co Ltd's management wants to use your money to grow the business. In return you get a share of Neopharm Co Ltd.

What can you expect buying and holding a share of Neopharm Co Ltd?

First you should know what it really means to hold a share of Neopharm Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Neopharm Co Ltd is ₩26,000. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neopharm Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neopharm Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩20,462.03. Based on the TTM, the Book Value Change Per Share is ₩569.49 per quarter. Based on the YOY, the Book Value Change Per Share is ₩380.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neopharm Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.540.0%0.520.0%0.380.0%0.370.0%0.370.0%
Usd Book Value Change Per Share0.540.0%0.400.0%0.270.0%0.840.0%0.840.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.540.0%0.400.0%0.270.0%0.840.0%0.840.0%
Usd Price Per Share18.10-16.71-14.23-21.91-21.91-
Price to Earnings Ratio8.42-8.26-9.36-9.78-9.78-
Price-to-Total Gains Ratio33.60-57.07--63.41-16.05-16.05-
Price to Book Ratio1.26-1.23-1.17-1.45-1.45-
Price-to-Total Gains Ratio33.60-57.07--63.41-16.05-16.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share18.2
Number of shares54
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.400.84
Usd Total Gains Per Share0.400.84
Gains per Quarter (54 shares)21.5345.50
Gains per Year (54 shares)86.11181.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1086760182172
201721620364354
302582480546536
403443340728718
504314200910900
60517506010921082
70603592012741264
80689678014561446
90775764016381628
100861850018201810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%17.00.00.0100.0%17.00.00.0100.0%17.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%15.02.00.088.2%15.02.00.088.2%15.02.00.088.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%15.02.00.088.2%15.02.00.088.2%15.02.00.088.2%

Fundamentals of Neopharm Co Ltd

About Neopharm Co Ltd

  • Other

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Neopharm Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neopharm Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • A Net Profit Margin of 22.1% means that ₩0.22 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neopharm Co Ltd:

  • The MRQ is 22.1%. The company is making a huge profit. +2
  • The TTM is 24.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ22.1%TTM24.0%-1.9%
TTM24.0%YOY20.1%+3.9%
TTM24.0%5Y21.8%+2.1%
5Y21.8%10Y21.8%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ22.1%5.6%+16.5%
TTM24.0%5.4%+18.6%
YOY20.1%6.9%+13.2%
5Y21.8%6.1%+15.7%
10Y21.8%6.1%+15.7%
1.1.2. Return on Assets

Shows how efficient Neopharm Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • 3.4% Return on Assets means that Neopharm Co Ltd generated ₩0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neopharm Co Ltd:

  • The MRQ is 3.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.4%TTM3.5%-0.1%
TTM3.5%YOY2.8%+0.6%
TTM3.5%5Y3.5%-0.1%
5Y3.5%10Y3.5%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4%1.0%+2.4%
TTM3.5%1.0%+2.5%
YOY2.8%1.5%+1.3%
5Y3.5%1.2%+2.3%
10Y3.5%1.4%+2.1%
1.1.3. Return on Equity

Shows how efficient Neopharm Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • 3.8% Return on Equity means Neopharm Co Ltd generated ₩0.04 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neopharm Co Ltd:

  • The MRQ is 3.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.8%TTM3.8%-0.1%
TTM3.8%YOY3.1%+0.7%
TTM3.8%5Y4.0%-0.2%
5Y4.0%10Y4.0%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8%3.2%+0.6%
TTM3.8%3.3%+0.5%
YOY3.1%4.9%-1.8%
5Y4.0%3.8%+0.2%
10Y4.0%3.8%+0.2%

1.2. Operating Efficiency of Neopharm Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neopharm Co Ltd is operating .

  • Measures how much profit Neopharm Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neopharm Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y12.0%-12.0%
5Y12.0%10Y12.0%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-10.7%
TTM-9.8%-9.8%
YOY-8.9%-8.9%
5Y12.0%6.0%+6.0%
10Y12.0%7.2%+4.8%
1.2.2. Operating Ratio

Measures how efficient Neopharm Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 1.10 means that the operating costs are ₩1.10 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Neopharm Co Ltd:

  • The MRQ is 1.104. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.065. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.104TTM1.065+0.038
TTM1.065YOY1.063+0.002
TTM1.0655Y1.036+0.029
5Y1.03610Y1.0360.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1041.249-0.145
TTM1.0651.260-0.195
YOY1.0631.216-0.153
5Y1.0361.257-0.221
10Y1.0361.355-0.319

1.3. Liquidity of Neopharm Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neopharm Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 7.94 means the company has ₩7.94 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Neopharm Co Ltd:

  • The MRQ is 7.938. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.983. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.938TTM8.983-1.046
TTM8.983YOY9.497-0.514
TTM8.9835Y8.373+0.610
5Y8.37310Y8.3730.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9381.436+6.502
TTM8.9831.515+7.468
YOY9.4971.526+7.971
5Y8.3731.478+6.895
10Y8.3731.478+6.895
1.3.2. Quick Ratio

Measures if Neopharm Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • A Quick Ratio of 6.41 means the company can pay off ₩6.41 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neopharm Co Ltd:

  • The MRQ is 6.413. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.232. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.413TTM7.232-0.819
TTM7.232YOY7.824-0.592
TTM7.2325Y6.934+0.297
5Y6.93410Y6.9340.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4130.566+5.847
TTM7.2320.604+6.628
YOY7.8240.606+7.218
5Y6.9340.608+6.326
10Y6.9340.603+6.331

1.4. Solvency of Neopharm Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neopharm Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neopharm Co Ltd to Other industry mean.
  • A Debt to Asset Ratio of 0.10 means that Neopharm Co Ltd assets are financed with 9.8% credit (debt) and the remaining percentage (100% - 9.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neopharm Co Ltd:

  • The MRQ is 0.098. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.096. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.098TTM0.096+0.003
TTM0.096YOY0.093+0.002
TTM0.0965Y0.116-0.020
5Y0.11610Y0.1160.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0980.531-0.433
TTM0.0960.535-0.439
YOY0.0930.551-0.458
5Y0.1160.567-0.451
10Y0.1160.572-0.456
1.4.2. Debt to Equity Ratio

Measures if Neopharm Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neopharm Co Ltd to the Other industry mean.
  • A Debt to Equity ratio of 10.9% means that company has ₩0.11 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neopharm Co Ltd:

  • The MRQ is 0.109. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.106. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.109TTM0.106+0.003
TTM0.106YOY0.104+0.002
TTM0.1065Y0.133-0.027
5Y0.13310Y0.1330.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1091.105-0.996
TTM0.1061.100-0.994
YOY0.1041.186-1.082
5Y0.1331.327-1.194
10Y0.1331.473-1.340

2. Market Valuation of Neopharm Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Neopharm Co Ltd generates.

  • Above 15 is considered overpriced but always compare Neopharm Co Ltd to the Other industry mean.
  • A PE ratio of 8.42 means the investor is paying ₩8.42 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neopharm Co Ltd:

  • The EOD is 8.467. Based on the earnings, the company is underpriced. +1
  • The MRQ is 8.418. Based on the earnings, the company is underpriced. +1
  • The TTM is 8.256. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD8.467MRQ8.418+0.049
MRQ8.418TTM8.256+0.162
TTM8.256YOY9.365-1.108
TTM8.2565Y9.783-1.527
5Y9.78310Y9.7830.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD8.46713.243-4.776
MRQ8.41810.893-2.475
TTM8.25610.521-2.265
YOY9.36511.319-1.954
5Y9.78312.391-2.608
10Y9.78312.665-2.882
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neopharm Co Ltd:

  • The EOD is -4.235. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.211. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 6.076. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-4.235MRQ-4.211-0.024
MRQ-4.211TTM6.076-10.287
TTM6.076YOY12.442-6.366
TTM6.0765Y10.593-4.517
5Y10.59310Y10.5930.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-4.2354.283-8.518
MRQ-4.2113.977-8.188
TTM6.0765.128+0.948
YOY12.4421.969+10.473
5Y10.5931.965+8.628
10Y10.5933.382+7.211
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neopharm Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of 1.26 means the investor is paying ₩1.26 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Neopharm Co Ltd:

  • The EOD is 1.271. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.263. Based on the equity, the company is underpriced. +1
  • The TTM is 1.228. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.271MRQ1.263+0.007
MRQ1.263TTM1.228+0.036
TTM1.228YOY1.173+0.055
TTM1.2285Y1.452-0.224
5Y1.45210Y1.4520.000
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD1.2711.661-0.390
MRQ1.2631.264-0.001
TTM1.2281.265-0.037
YOY1.1731.435-0.262
5Y1.4521.483-0.031
10Y1.4521.612-0.160
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Neopharm Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--769.274569.492+35%380.592+102%1203.649-36%1203.649-36%
Book Value Per Share--20462.03419389.847+6%17418.812+17%14061.028+46%14061.028+46%
Current Ratio--7.9388.983-12%9.497-16%8.373-5%8.373-5%
Debt To Asset Ratio--0.0980.096+3%0.093+5%0.116-15%0.116-15%
Debt To Equity Ratio--0.1090.106+3%0.104+5%0.133-18%0.133-18%
Dividend Per Share----0%-0%-0%-0%
Eps--767.684742.037+3%544.299+41%523.763+47%523.763+47%
Free Cash Flow Per Share---1534.74277.831-2072%554.753-377%491.629-412%491.629-412%
Free Cash Flow To Equity Per Share---1534.74277.831-2072%554.753-377%491.629-412%491.629-412%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---126051.390--------
Intrinsic Value_10Y_min---103976.220--------
Intrinsic Value_1Y_max---334.603--------
Intrinsic Value_1Y_min---321.433--------
Intrinsic Value_3Y_max---10376.806--------
Intrinsic Value_3Y_min---9717.366--------
Intrinsic Value_5Y_max---31717.360--------
Intrinsic Value_5Y_min---28632.651--------
Market Cap--202163233800.000186678390360.000+8%158954264100.000+27%180902856582.000+12%180902856582.000+12%
Net Profit Margin--0.2210.240-8%0.201+10%0.218+1%0.218+1%
Operating Margin----0%-0%0.120-100%0.120-100%
Operating Ratio--1.1041.065+4%1.063+4%1.036+6%1.036+6%
Pb Ratio1.271+1%1.2631.228+3%1.173+8%1.452-13%1.452-13%
Pe Ratio8.467+1%8.4188.256+2%9.365-10%9.783-14%9.783-14%
Price Per Share26000.000+1%25850.00023870.000+8%20325.000+27%31296.500-17%31296.500-17%
Price To Free Cash Flow Ratio-4.235-1%-4.2116.076-169%12.442-134%10.593-140%10.593-140%
Price To Total Gains Ratio33.798+1%33.60357.066-41%-63.407+289%16.048+109%16.048+109%
Quick Ratio--6.4137.232-11%7.824-18%6.934-8%6.934-8%
Return On Assets--0.0340.035-2%0.028+19%0.035-5%0.035-5%
Return On Equity--0.0380.038-2%0.031+19%0.040-7%0.040-7%
Total Gains Per Share--769.274569.492+35%380.592+102%1203.649-36%1203.649-36%
Usd Book Value--112018167.576106148546.870+6%95358235.936+17%85901210.606+30%85901210.606+30%
Usd Book Value Change Per Share--0.5380.399+35%0.266+102%0.843-36%0.843-36%
Usd Book Value Per Share--14.32313.573+6%12.193+17%9.843+46%9.843+46%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.5370.519+3%0.381+41%0.367+47%0.367+47%
Usd Free Cash Flow---8401854.132426080.106-2072%3036964.133-377%2616638.419-421%2616638.419-421%
Usd Free Cash Flow Per Share---1.0740.054-2072%0.388-377%0.344-412%0.344-412%
Usd Free Cash Flow To Equity Per Share---1.0740.054-2072%0.388-377%0.344-412%0.344-412%
Usd Market Cap--141514263.660130674873.252+8%111267984.870+27%126631999.607+12%126631999.607+12%
Usd Price Per Share18.200+1%18.09516.709+8%14.228+27%21.908-17%21.908-17%
Usd Profit--4202637.9994062239.319+3%2979731.953+41%3336527.224+26%3336527.224+26%
Usd Revenue--19049235.62516993355.836+12%14880799.190+28%15222705.019+25%15222705.019+25%
Usd Total Gains Per Share--0.5380.399+35%0.266+102%0.843-36%0.843-36%
 EOD+3 -3MRQTTM+15 -17YOY+20 -125Y+17 -1610Y+17 -16

3.2. Fundamental Score

Let's check the fundamental score of Neopharm Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.467
Price to Book Ratio (EOD)Between0-11.271
Net Profit Margin (MRQ)Greater than00.221
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.413
Current Ratio (MRQ)Greater than17.938
Debt to Asset Ratio (MRQ)Less than10.098
Debt to Equity Ratio (MRQ)Less than10.109
Return on Equity (MRQ)Greater than0.150.038
Return on Assets (MRQ)Greater than0.050.034
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Neopharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.947
Ma 20Greater thanMa 5024,052.500
Ma 50Greater thanMa 10024,799.000
Ma 100Greater thanMa 20025,587.000
OpenGreater thanClose25,900.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  0000000-1-1



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets177,458,519
Total Liabilities17,432,565
Total Stockholder Equity160,025,954
 As reported
Total Liabilities 17,432,565
Total Stockholder Equity+ 160,025,954
Total Assets = 177,458,519

Assets

Total Assets177,458,519
Total Current Assets134,502,291
Long-term Assets42,956,228
Total Current Assets
Cash And Cash Equivalents 11,880,925
Short-term Investments 100,109,084
Net Receivables 8,555,176
Inventory 10,195,003
Other Current Assets 932,051
Total Current Assets  (as reported)134,502,291
Total Current Assets  (calculated)131,672,239
+/- 2,830,052
Long-term Assets
Property Plant Equipment 29,244,087
Intangible Assets 2,236,859
Long-term Assets  (as reported)42,956,228
Long-term Assets  (calculated)31,480,946
+/- 11,475,282

Liabilities & Shareholders' Equity

Total Current Liabilities16,944,787
Long-term Liabilities487,778
Total Stockholder Equity160,025,954
Total Current Liabilities
Short Long Term Debt 17,677
Accounts payable 6,434,825
Other Current Liabilities -1
Total Current Liabilities  (as reported)16,944,787
Total Current Liabilities  (calculated)6,452,501
+/- 10,492,286
Long-term Liabilities
Long-term Liabilities  (as reported)487,778
Long-term Liabilities  (calculated)0
+/- 487,778
Total Stockholder Equity
Retained Earnings 113,603,270
Total Stockholder Equity (as reported)160,025,954
Total Stockholder Equity (calculated)113,603,270
+/- 46,422,683
Other
Capital Stock4,103,681
Common Stock Shares Outstanding 7,821
Net Invested Capital 160,043,631
Net Working Capital 117,557,504
Property Plant and Equipment Gross 37,890,120



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
74,550,109
108,218,790
111,355,022
122,741,537
127,680,001
125,038,931
126,113,926
132,977,764
141,121,325
138,736,100
141,326,772
143,408,029
148,926,067
147,579,706
149,080,164
155,347,427
162,289,799
161,714,685
169,263,364
177,458,519
177,458,519169,263,364161,714,685162,289,799155,347,427149,080,164147,579,706148,926,067143,408,029141,326,772138,736,100141,121,325132,977,764126,113,926125,038,931127,680,001122,741,537111,355,022108,218,79074,550,109
   > Total Current Assets 
60,642,286
93,972,080
95,845,416
101,680,179
106,523,986
105,148,608
106,576,970
113,551,469
121,876,318
116,792,984
119,134,087
121,483,815
127,315,441
125,407,162
124,338,430
131,270,044
138,342,251
137,490,317
147,151,897
134,502,291
134,502,291147,151,897137,490,317138,342,251131,270,044124,338,430125,407,162127,315,441121,483,815119,134,087116,792,984121,876,318113,551,469106,576,970105,148,608106,523,986101,680,17995,845,41693,972,08060,642,286
       Cash And Cash Equivalents 
7,877,379
4,433,438
4,656,444
5,515,261
6,878,164
5,380,143
8,785,575
11,188,730
12,081,572
8,679,401
8,599,407
7,048,975
16,337,211
8,826,460
7,802,800
10,882,863
15,769,601
17,287,766
11,512,806
11,880,925
11,880,92511,512,80617,287,76615,769,60110,882,8637,802,8008,826,46016,337,2117,048,9758,599,4078,679,40112,081,57211,188,7308,785,5755,380,1436,878,1645,515,2614,656,4444,433,4387,877,379
       Short-term Investments 
33,009,012
72,016,346
74,371,072
80,011,517
82,012,184
81,002,915
80,005,386
84,992,058
90,000,021
90,000,000
92,000,001
98,000,000
92,000,000
97,000,000
97,000,000
102,602,498
102,605,807
100,605,256
112,896,474
100,109,084
100,109,084112,896,474100,605,256102,605,807102,602,49897,000,00097,000,00092,000,00098,000,00092,000,00190,000,00090,000,02184,992,05880,005,38681,002,91582,012,18480,011,51774,371,07272,016,34633,009,012
       Net Receivables 
9,436,221
8,923,868
8,360,448
8,902,823
7,537,208
7,954,199
7,451,119
8,321,963
9,691,049
7,767,376
8,300,606
7,512,904
7,864,390
6,931,447
6,936,981
6,542,811
7,267,931
8,025,004
8,862,123
8,555,176
8,555,1768,862,1238,025,0047,267,9316,542,8116,936,9816,931,4477,864,3907,512,9048,300,6067,767,3769,691,0498,321,9637,451,1197,954,1997,537,2088,902,8238,360,4488,923,8689,436,221
       Inventory 
8,302,754
7,411,009
7,316,382
5,840,464
8,180,805
9,084,105
8,362,333
8,089,751
9,093,379
9,381,632
8,881,081
7,973,482
9,516,244
10,915,011
10,306,804
8,749,037
9,470,047
8,762,125
10,700,356
10,195,003
10,195,00310,700,3568,762,1259,470,0478,749,03710,306,80410,915,0119,516,2447,973,4828,881,0819,381,6329,093,3798,089,7518,362,3339,084,1058,180,8055,840,4647,316,3827,411,0098,302,754
   > Long-term Assets 
13,907,823
14,246,710
15,509,607
21,061,359
21,156,014
19,890,323
19,536,957
19,426,295
19,245,007
21,943,116
22,192,684
21,924,213
21,610,627
22,172,544
24,741,733
24,077,383
23,947,548
24,224,368
22,111,468
42,956,228
42,956,22822,111,46824,224,36823,947,54824,077,38324,741,73322,172,54421,610,62721,924,21322,192,68421,943,11619,245,00719,426,29519,536,95719,890,32321,156,01421,061,35915,509,60714,246,71013,907,823
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,242,885
9,341,045
9,175,044
8,940,848
9,080,133
29,244,087
29,244,0879,080,1338,940,8489,175,0449,341,0459,242,88500000000000000
       Intangible Assets 
1,147,860
2,312,249
2,631,062
2,384,017
2,525,992
2,550,183
2,474,653
2,380,417
2,285,581
2,207,826
2,143,127
2,055,108
1,970,197
1,873,699
1,827,605
1,786,490
1,682,788
2,086,734
2,047,446
2,236,859
2,236,8592,047,4462,086,7341,682,7881,786,4901,827,6051,873,6991,970,1972,055,1082,143,1272,207,8262,285,5812,380,4172,474,6532,550,1832,525,9922,384,0172,631,0622,312,2491,147,860
       Long-term Assets Other 
13,907,823
0
0
1
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
-1
-100000000010100010013,907,823
> Total Liabilities 
14,969,791
12,568,143
11,587,047
17,048,924
22,524,408
15,370,467
13,499,400
15,260,215
22,581,022
16,161,210
15,741,609
13,103,096
19,169,854
13,099,691
10,622,991
13,136,622
18,877,430
12,599,629
15,253,617
17,432,565
17,432,56515,253,61712,599,62918,877,43013,136,62210,622,99113,099,69119,169,85413,103,09615,741,60916,161,21022,581,02215,260,21513,499,40015,370,46722,524,40817,048,92411,587,04712,568,14314,969,791
   > Total Current Liabilities 
14,456,863
11,626,370
11,112,814
12,831,106
18,269,957
11,179,142
9,092,290
14,876,598
22,216,503
15,903,430
15,071,267
12,940,760
18,983,029
13,085,488
10,622,991
13,136,622
18,877,430
12,599,629
15,084,403
16,944,787
16,944,78715,084,40312,599,62918,877,43013,136,62210,622,99113,085,48818,983,02912,940,76015,071,26715,903,43022,216,50314,876,5989,092,29011,179,14218,269,95712,831,10611,112,81411,626,37014,456,863
       Short-term Debt 
0
0
400,000
419,940
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000419,940400,00000
       Short Long Term Debt 
0
0
400,000
419,940
419,940
419,749
19,749
4,019,749
4,019,749
4,019,266
4,019,266
19,266
19,266
19,266
18,586
18,586
18,586
17,677
17,677
17,677
17,67717,67717,67718,58618,58618,58619,26619,26619,2664,019,2664,019,2664,019,7494,019,74919,749419,749419,940419,940400,00000
       Accounts payable 
2,689,242
1,999,783
3,008,780
3,173,662
4,512,334
4,039,744
2,801,206
4,194,096
4,794,115
3,929,664
3,552,369
4,347,009
4,794,098
4,982,106
3,456,545
3,703,218
4,798,529
4,136,372
6,340,816
6,434,825
6,434,8256,340,8164,136,3724,798,5293,703,2183,456,5454,982,1064,794,0984,347,0093,552,3693,929,6644,794,1154,194,0962,801,2064,039,7444,512,3343,173,6623,008,7801,999,7832,689,242
       Other Current Liabilities 
0
-1
0
-1
0
1
0
0
1
1
0
0
1
2
1
0
0
1
0
-1
-1010012100110010-10-10
   > Long-term Liabilities 
512,929
941,773
474,232
4,217,817
4,254,450
4,191,326
4,407,111
383,618
364,519
257,781
670,343
162,336
186,825
14,203
0
0
0
0
169,215
487,778
487,778169,215000014,203186,825162,336670,343257,781364,519383,6184,407,1114,191,3264,254,4504,217,817474,232941,773512,929
       Long term Debt 
400,000
400,000
0
4,000,000
4,000,000
4,000,000
4,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000004,000,0004,000,0004,000,0004,000,0000400,000400,000
       Capital Lease Obligations Min Short Term Debt
0
113,885
-366,335
-163,599
225,952
145,792
65,277
290,023
210,005
129,682
356,788
539,502
418,140
296,191
173,654
393,576
262,269
132,435
394,241
1,047,620
1,047,620394,241132,435262,269393,576173,654296,191418,140539,502356,788129,682210,005290,02365,277145,792225,952-163,599-366,335113,8850
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000
> Total Stockholder Equity
59,580,317
95,650,647
99,767,976
105,692,614
105,155,593
109,668,464
112,614,526
117,717,549
118,540,302
122,574,889
125,585,162
130,304,933
129,756,213
134,480,016
138,457,172
142,210,805
143,412,369
149,115,055
154,009,747
160,025,954
160,025,954154,009,747149,115,055143,412,369142,210,805138,457,172134,480,016129,756,213130,304,933125,585,162122,574,889118,540,302117,717,549112,614,526109,668,464105,155,593105,692,61499,767,97695,650,64759,580,317
   Common Stock00000000000000000000
   Retained Earnings 
43,053,339
47,139,726
51,265,878
57,206,352
56,066,478
60,588,738
63,533,328
68,635,315
71,929,432
76,038,608
79,094,564
83,848,462
83,405,159
88,290,588
92,499,392
96,106,467
97,251,825
102,831,104
107,762,298
113,603,270
113,603,270107,762,298102,831,10497,251,82596,106,46792,499,39288,290,58883,405,15983,848,46279,094,56476,038,60871,929,43268,635,31563,533,32860,588,73856,066,47857,206,35251,265,87847,139,72643,053,339
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 00000000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue97,104,890
Cost of Revenue-31,719,585
Gross Profit65,385,30565,385,305
 
Operating Income (+$)
Gross Profit65,385,305
Operating Expense-71,797,585
Operating Income25,307,305-6,412,280
 
Operating Expense (+$)
Research Development2,647,403
Selling General Administrative25,336,158
Selling And Marketing Expenses0
Operating Expense71,797,58527,983,561
 
Net Interest Income (+$)
Interest Income4,587,925
Interest Expense-21,323
Other Finance Cost-0
Net Interest Income4,566,602
 
Pretax Income (+$)
Operating Income25,307,305
Net Interest Income4,566,602
Other Non-Operating Income Expenses0
Income Before Tax (EBT)29,373,28725,307,305
EBIT - interestExpense = -21,323
23,212,796
23,234,119
Interest Expense21,323
Earnings Before Interest and Taxes (EBIT)029,394,610
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax29,373,287
Tax Provision-6,160,491
Net Income From Continuing Ops23,212,79623,212,796
Net Income23,212,796
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-4,566,602
 

Technical Analysis of Neopharm Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neopharm Co Ltd. The general trend of Neopharm Co Ltd is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neopharm Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neopharm Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 26,000 < 28,600 < 29,450.

The bearish price targets are: 25,450 > 25,450 > 22,350.

Tweet this
Neopharm Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neopharm Co Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neopharm Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neopharm Co Ltd. The current macd is 283.69.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neopharm Co Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Neopharm Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Neopharm Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neopharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartNeopharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neopharm Co Ltd. The current adx is 22.07.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neopharm Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Neopharm Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neopharm Co Ltd. The current sar is 23,217.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neopharm Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neopharm Co Ltd. The current rsi is 62.95. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Neopharm Co Ltd Daily Relative Strength Index (RSI) ChartNeopharm Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neopharm Co Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neopharm Co Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Neopharm Co Ltd Daily Stochastic Oscillator ChartNeopharm Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neopharm Co Ltd. The current cci is 154.63.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Neopharm Co Ltd Daily Commodity Channel Index (CCI) ChartNeopharm Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neopharm Co Ltd. The current cmo is 39.42.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neopharm Co Ltd Daily Chande Momentum Oscillator (CMO) ChartNeopharm Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neopharm Co Ltd. The current willr is -17.04545455.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Neopharm Co Ltd Daily Williams %R ChartNeopharm Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Neopharm Co Ltd.

Neopharm Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neopharm Co Ltd. The current atr is 904.60.

Neopharm Co Ltd Daily Average True Range (ATR) ChartNeopharm Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neopharm Co Ltd. The current obv is 1,676,018.

Neopharm Co Ltd Daily On-Balance Volume (OBV) ChartNeopharm Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neopharm Co Ltd. The current mfi is 76.57.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Neopharm Co Ltd Daily Money Flow Index (MFI) ChartNeopharm Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neopharm Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Neopharm Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neopharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.947
Ma 20Greater thanMa 5024,052.500
Ma 50Greater thanMa 10024,799.000
Ma 100Greater thanMa 20025,587.000
OpenGreater thanClose25,900.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Neopharm Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Neopharm Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neopharm Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neopharm Co Ltd

I send you an email if I find something interesting about Neopharm Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Neopharm Co Ltd.

Receive notifications about Neopharm Co Ltd in your mailbox!